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Objective: To compare the effects of standard silicone oil 5700 (SSO) and heavy silicone oil 
(HSO) such as Densiron® 68 on intraocular pressure (IOP).
Materials and methods: Retrospective case series including 180 eyes (105 treated with SSO 
and 75 with HSO). IOP was measured before surgery, 1 day after, and then at 1-, 3-, 6-, and 
12-month follow-ups.
Results: In the SSO group, a significant increase in IOP occurred in 14% of the eyes (15/105) at 
1 day postoperatively, and persisted in 11.4% (12/105) at 1-month follow-up. In the HSO group, 
a persistent elevated IOP was recorded in 20% of the eyes (15/75) at 1 day postoperatively, and 
in 16% (12/75) at 1-month follow-up. At 12-month follow-up, mean IOP was 16.7 ± 8.7 mmHg 
and 19.7 ± 3.8 mmHg, respectively, in the SSO and HSO groups. The difference between the 
2 groups was always not significant.
Conclusion: Overall, the use of Densiron 68 was not associated with higher IOP values as 
compared with SSO.
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Introduction
The use of silicone oil (SO) in conjunction with advanced vitreous surgical techniques 
can successfully treat complicated retinal detachment (RD),1–4 including proliferative 
vitreoretinopathy, giant retinal tears, and severe trauma cases.5,6 SO is still the best-
tolerated substance and is well-accepted and biologically well-tolerated in the clinical 
management of complicated conditions. Because the specific gravity of standard 
silicone oil (SSO) (0.97 g/cm3) is lower than that of water, it has an effective tampon-
ade effect for the treatment of retinal pathologies in the upper quadrants. The most 
frequent complication with SSO internal tamponade is the persistence or recurrence 
of inferior RD.7,8
Several attempts have been undertaken to develop a vitreous tamponade with a 
specific gravity greater than that of water.9,10 Recently, partially fluorinated alkanes in 
combination with SSO have been proposed as heavy tamponade agents for long-term 
tamponade. The combination of these 2 substances results in a single-bubble optically 
clear mixture according to the proportions used.11–13
Densiron® 68 (Fluoron Gmbh, Neu-Ulm, Germany) is a solution of SSO and 
perfluorohexyloctane (F6H8). By adding F6H8 to silicone, the mixture has a specific 
gravity of 1.06 g/cm3 and a viscosity of 1387 centistokes (cSt). It is therefore heavier 
than water and sufficiently viscous to have a much lower propensity for dispersion 
(compared with F6H8 on its own). Therefore, the advantage of long-term heavy Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Dovepress
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  tamponades with a specific gravity greater than that of water 
is to provide an effective postoperative tamponade of the 
inferior quadrants.
Long-term glaucoma following SSO use is uncommon in 
current surgery, but past studies have indicated an incidence 
ranging from 3% to 40% of cases.4,10,14,15 Some of these cases can 
develop secondary glaucoma.5,14–16 The Silicone Study Report 
4 has recently recorded a prevalence of chronically elevated 
intraocular pressure (IOP) in 8% of patients with SSO.17
The aim of this study was to compare IOP modifications 
in eyes treated with SSO versus heavy silicone oil (HSO) 
(Densiron 68) in the management of complicated RD.
Materials and methods
study design
We performed a retrospective case study of 180 eyes of 
180 patients: 105 eyes (65 phakic, 35 pseudophakic, 5 aphakic) 
treated with SSO 5700 cSt (Oxane 5700®; Bausch and Lomb 
Inc., Toulouse, France) and 75 eyes (57 phakic, 15 pseudopha-
kic, 3 aphakic) treated with Densiron 68 tamponade.
All cases were treated from June 2006 to January 2008 in 
3 different centers in Italy by 5 different vitreoretinal surgeons. 
The exclusion criteria were severe systemic disease, preg-
nancy, and pre-existing ocular inflammatory disease.
Patients and preoperative findings
The mean age in the first group was 64 ± 21 (15–81) years and 
in the second group 58 ± 15 (13–90) years. IOP was measured 
before surgery, 1 day after surgery, and then at 1-, 3-, 6-, 
and 12-month follow-ups. SSO removal was planned within 
6 months (160 ± 35 days), whereas Densiron 68 removal was 
planned within 3 months (130 ± 15 days) from the initial 
surgery, according to the presence of emulsification. The 
reason for such a difference is that Densiron 68 contains 
F6H8, which might lead to a higher rate of inflammation 
in cases of long-term endotamponade. The following 
preoperative and postoperative parameters were recorded: 
etiology of RD, refractive status, pre-existing glaucoma, 
lens status, diabetes mellitus, presence of SSO in the anterior 
chamber, emulsification of SSO, and rubeosis iridis. Given 
the retrospective nature of this study, gonioscopy data were 
not available in all cases, and therefore such parameters have 
not been included in the study design. The baseline patient 
parameters are summarized in Table 1.
surgical techniques
The indication for surgery and for use of oil as endotam-
ponade was mainly RD. Moreover, 11 cases (4 in the SSO 
group and 7 in the HSO group) underwent surgery for stage 
4 macular hole or reopening macular hole.
Surgery was performed with monitored anesthesia care and 
a retrobulbar block. In both groups the surgical procedure 
included a standard 3-port pars plana vitrectomy using the 
ACCURUS® System (Alcon Laboratories, Inc., Hünenberg, 
Switzerland) or Associate® System (DORC, Zuidland, the 
Netherlands) for vitrectomy. During vitrectomy, the vitreous 
base was thoroughly removed. Epiretinal membrane dissection 
and relaxing retinotomies were performed, when necessary. 
The retinal periphery was inspected for retinal breaks, and any 
break found was treated with cryocoagulation or endolaser 
photocoagulation. A fluid–air exchange procedure was then 
performed with humidified air.
At the end of the surgical procedure, SSO or HSO 
(  Densiron 68) was injected by an automatic device. HSO with 
an interfacial tension against water at 25°C of 40.82 mN/m, 
a specific gravity of 1.06 g/cm3, and a viscosity of 1387 cSt 
was used. The SSO used was of 5700 cSt viscosity at 25°C, 
with a specific gravity of 0.965 g/cm3 and interfacial tension 
against water at 25°C of 35.5 mN/m. The iridotomies were 
performed in aphakic eyes: inferior iridotomy in the SSO 
group and superior iridotomy in the HSO group. At the end 
of surgery the eye appeared clinically completely filled by the 
substance. Suture of the sclerotomies followed. In all cases the 
surgery was not combined with scleral buckle placement.
examinations
IOP was recorded using the Goldmann applanation tonometer. 
The presence of ocular hypertension (OH) was defined as 
postoperatively elevated IOP greater than 25 mmHg, or with a 
value greater than 10 mmHg above the preoperative level.
As this work was performed as an audit, our hospital did 
not require the study to have a specific ethical approval.
Table 1 Baseline patient characteristics
Group No. eyes Gender (M/F) Age (years) Lens status  
(Ph/Pseph/Aph)
Removal of oil
ssO 5700 105 34/73 64 ± 21 (15–81) 65/35/5 160 ± 35 days
Densiron 68 75 45/30 58 ± 15 (13–90) 57/15/3 130 ± 15 days
Abbreviations: M, male; F, female; Ph, phakic; Pseph, pseudophakic; Aph, aphakic; ssO, standard silicone oil.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Results
We report functional and anatomical results, with particular 
attention given to differences in IOP and to the presence of 
SSO in the anterior chamber (AC). Moreover, we investigated 
the depth of the AC and the retinal status at the follow-up 
checks. Statistical analysis was performed using SPSS 
  software version 10 (SPSS Inc., Chicago, IL, USA).
iOP
OH occurred in 14% of the eyes (15 out of 105) at 1 day 
postoperatively, and persisted in 11.4% of the eyes (12 
out of 105) at 1-month follow-up in the presence of SSO. 
In the HSO group, OH occurred in 20% of the eyes (15 out 
of 75) at 1 day postoperatively, and persisted in 16% of the 
eyes (12 out of 75) at 1-month follow-up. The differences 
between the 2 groups were always not significant (P = 0.18, 
chi-square test). In the SSO group at 3-month follow-up, 
IOP was controlled in 12 of 15 eyes (81%), 45% with topical 
treatment (beta-blockers, dorzolamide, and brinzolamide), 
30% with oral treatment (acetazomide), and 6% with other 
surgical procedures; in the HSO group at 3-month follow-up, 
IOP was controlled in 11 of 15 eyes (73%), 40% with topi-
cal treatment, 20% with oral treatment, and 13% with other 
surgical procedures. In the SSO group, mean postoperative 
IOP values at 1-day and 1-, 3-, and 6-month follow-up were 
22.8 ± 8.9, 22.3 ± 7.4, 20.5 ± 9.5, and 18.6 ± 8.4 mmHg, 
respectively. In the HSO group, mean postoperative IOP 
values at 1-day and 1-, 3-, and 6-month follow-up were 
23.4 ± 5.7, 21.8 ± 6.4, 22.3 ± 9.2, and 18.9 ± 8.7, respectively. 
At 12-month follow-up, mean IOP was 16.7 ± 8.7 mmHg and 
19.7 ± 3.8 mmHg in the SSO and HSO groups, respectively 
(Figure 1). The difference in IOP between the 2 groups 
was not statistically significant (P = 0.21, chi-square test). 
At 12-month follow-up, 7.6% of patients (8 out of 105) in the 
SSO group and 10.6% of patients (8 out of 75) in the HSO 
group were still on topical treatment for glaucoma (in most 
cases with a combination of topical dorzolamide–timolol).
One case (0.95%) in the SSO group and 2 cases (2.6%) 
in the HSO group needed surgical treatment with trabeculec-
tomy to lower IOP.
The trabeculectomy was performed after the removal of 
oil in both groups. The patients did not develop neovascular 
glaucoma but showed a persistent elevated IOP, probably 
due to the emulsified SSO, which may induce changes in 
the trabecular meshwork with a reduction in the outflow of 
aqueous humor.
The oil was removed when necessary in relation to AC 
inflammation, emulsification, and the presence of a well-
formed chorioretinal scar. Therefore, the mean time for 
removal of HSO was shorter than for SSO. This could influ-
ence the IOP results at the 3-month follow-up but not the 
final 12-month follow-up.
The clinical data of patients are summarized in Table 2 
and Table 3.
Anatomical results
Anatomical success was defined as complete retinal reattach-
ment without the presence of any endotamponade. Because 
of its specific gravity, SSO does not provide adequate support 
to the inferior retina, which HSO provides for the superior 
retina.
One month after the removal of oil, anatomical success 
was achieved in 92 out of 105 eyes (87.6%) in the SSO group. 
In this group we also noted an RD not involving the posterior 
pole in 2 out of 105 eyes (1.9%) in the superior quadrant and 
in 6 out of 105 eyes (5.7%) in the inferior quadrant. Thirteen 
eyes required further surgery (Table 3).
In the HSO group, anatomical success was achieved in 64 
out of 75 eyes (85.3%). An RD not involving the posterior 
pole was noted in 3 out of 75 eyes (4%) in the superior quad-
rant, and in 4 out of 75 eyes (5.3%) in the inferior quadrant. 
Eleven eyes required further surgery. In all reattachments 
SSO was used as endotamponade (Table 3).
The best corrected visual acuity improved from 
1.21 ± 0.94 to 0.56 ± 0.51 logMar in the SSO group, and from 
1.74 ± 0.83 to 0.48 ± 0.81 logMar in the HSO group.
Anterior chamber findings
At 1-day follow-up, in the SSO group, a shallow AC was 
found in 2 eyes out of 105 (1.9%), which were both pseu-
dophakic. No oil was found in the AC of these patients.
1 day
0
5
10
15
20
25
1 mo 3 mo 6 mo 12 mo
SO
Densiron
Figure 1 Percentage of Oh in ssO and Densiron 68 group at each follow-up visit.a
Note:  aOh is defined as elevated IOP greater than 25 mmHg, or greater than 
10 mmhg above the preoperative level.
Abbreviations: Oh, ocular hypertension; ssO, standard silicone oil; mo, month; 
iOP, intraocular pressure.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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In the HSO group, a shallow AC was found in 4 out of 
75 eyes (5.3%): 3 pseudophakic and 1 aphakic. The presence 
of oil in the AC was recorded in 10 eyes (13.3%), 9 of which 
were pseudophakic and 1 aphakic.
Discussion
The cause of raised IOP following the use of endotamponade 
in the surgical treatment of complicated RD may be 
multifactorial, including inflammation, previous vitreoretinal 
procedures, and overfilling.16 Clinically significant increased 
IOP could represent a complication following vitreoretinal 
procedures, which can lead to the development of secondary 
glaucoma.18,19 Previous studies have reported effective 
control of IOP in this type of OH with medical and surgical 
procedures, with possible use of antimetabolites or filtration 
tubes.20,21
Henderer et al reported that 21% (80 out of 383 eyes) of 
patients treated with SSO for complex RD had an elevated 
IOP (greater than 25 mm Hg) at 12-month follow-up.22 These 
authors pointed out that risk factors for an elevated postopera-
tive IOP were a history of glaucoma, diabetes mellitus, and 
a high IOP on the first postoperative day.22
Wong et al reported a case-control study on 128 patients to 
compare the postoperative IOP in patients treated with HSO 
with those treated with SSO.23 At the first day and at 2 weeks 
postoperatively, mean IOP was higher in patients treated with 
HSO (P = 0.05 and 0.01, respectively). By the fourth week, 
the IOP difference between the 2 groups was insignificant 
(P = 0.17).23 On day 1, 12.7% eyes (9 out of 71) in the HSO 
group and 3.5% eyes (2 out of 57) in the SSO group had an 
IOP greater than 30 mmHg. At 4 weeks, an IOP of more than 
30 mmHg was still seen in 12.7% (9 out of 71) of the HSO-
treated group and in 1.8% (9 out of 57) in the SSO group.23 
In our series we did not find any significant IOP regression 
after removal of SSO or HSO.
In a series of 70 eyes of 70 patients, Tranos et al showed 
that although medical treatment is successful in lowering 
IOP in most patients, there was a mild progression of the 
mean vertical cup/disc ratio from 0.6 (SD 0.2) to 0.7 (SD 0.2) 
in the majority of patients during the follow-up period.24 
  Moreover, the visual outcome of eyes with final IOP greater 
than 21 mmHg was significantly worse than that exhibited 
by eyes with a normal (6–21 mmHg) IOP range.25
There are several important limitations to this study, 
including the retrospective nature, diurnal variation of 
IOP, and variety of surgeons, techniques, and instruments 
used. The analysis of SSO emulsification is complex due 
to the multifactorial etiology. The presence of red blood 
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cell membranes, plasma lipoproteins, purified high-density 
lipoprotein apolipoproteins, an encircling band, and even the 
oil/aqueous movement generated by high-speed vitrectomy 
handpieces result in shearing forces and support the SSO 
emulsification.22–26
To the best of our knowledge, there are no reports on 
long-term changes in IOP after the use of HSO.
In our series, there was no significant difference between 
the 2 groups, but there appeared to be a trend for somewhat 
higher values in the HSO group, both in the early postopera-
tive period and at longer follow-up times. Our findings could 
be explained by the different tendency for emulsification 
of the 2 tamponades.26 HSO and SSO are known to remain 
stable for 3 and 6 months, respectively.27,28 At the time of 
oil removal, some droplets may be involuntarily left in the 
vitreous cavity. Over time, these small amounts of tamponade 
may emulsify and then may induce a chronic reaction. The 
macrophages react toward the tamponade emulsion as if it 
were a foreign body, as already reported by Hiscott et al28 
for F6H8, and thus they are able to promote, theoretically, 
an IOP increase. This effect seems to be higher in the HSO 
group of patients.
In our series we did not report any case of pupillary 
block associated with SSO or HSO caused by overfilling 
of the globe at the end of surgery. We believe that the long-
term increased IOP depends on an open-angle mechanism 
rather than a closed-angle mechanism. We can speculate that 
the persistence of a raised pressure could be related to the 
presence of emulsificated oil in the AC and in the trabecular 
meshwork, which persists after the removal of oil.
A high IOP value on the first postoperative day represents 
a prognostic negative risk factor for the development of glau-
coma in long-term follow-up. In most cases, topical treatment 
is sufficient to keep the pressure under control. Prophylactic 
treatment should be considered in high-risk eyes.
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The authors declare no conflicts of interest.
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Table 3 Anatomical and functional outcomes at different follow-up intervals
Variable Baseline 1 day 1 month 3 month 6 month 12 month
SSO groupa
iOP 15.2 ± 3.1 22.8 ± 8.9 22.3 ± 7.4 20.5 ± 9.5 18.6 ± 8.4 16.7 ± 8.7
Anatomical success rate (%) 105 (100) 98 (93) 94 (89) 92 (88) 103 (98)
BCVA logMar 1.21 ± 0.94 1.01 ± 0.76 0.86 ± 0.35 0.94 ± 0.75 0.60 ± 0.54 0.56 ± 0.51
Presence of sO (in/out) 105/0 105/0 105/0 77/28 10/95 1/104
Densiron 68 groupb
iOP 14.8 ± 2.8 23.4 ± 5.7 21.8 ± 6.4 22.3 ± 9.2 18.9 ± 8.7 19.7 ± 3.8
Anatomical success rate (%) 75 (100) 72 (96) 68 (91) 64 (85) 74 (99)
BCVA logMar 1.74 ± 0.83 1.1 ± 0.79 0.78 ± 0.65 0.9 ± 0.84 0.68 ± 0.63 0.48 ± 0.81
Presence of Densiron 68 (in/out) 75/0 75/0 75/0 8/67 0/75 0/75
Notes: aMean time of sO removal was 160 ± 35 days; bMean time of sO removal was 130 ± 15 days.
Abbreviations: ssO, standard silicone oil; iOP, intraocular pressure; BCVA, best corrected visual acuity.Clinical Ophthalmology
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